<DOC>
	<DOCNO>NCT02577315</DOCNO>
	<brief_summary>Bioequivalence two 12.5 mg empagliflozin/500 mg metformin fix dose combination tablet compare free combination empagliflozin 25 mg metformin 1000 mg healthy male female volunteer feed condition</brief_summary>
	<brief_title>Demonstrate Bioequivalence Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination Empagliflozin 25 mg Metformin 1000 mg Healthy Male Female Volunteers Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject age 18 45 year BMI 18.50 24.99 kg/m2 Quetelet Signed informed consent prior admission study Subjects must able undergo trial related request procedure follow trial relate restriction concomitant medication , diet life style Subjects must neversmokers exsmokers stop smoke prior enrolment ( Visit 1 ) Male female subject use adequate contraception least 30 day first study drug administration 30 day trial completion Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal laboratory value outside reference range Positive result blood test infection ( HIV , Syphilis , Hepatitis B C ) , urine drug screen test alcohol breath test Any evidence concomitant disease judge clinically relevant investigator presence cardiovascular , respiratory , nervous , endocrine , reproductive , hematopoietic , immune system disorder ; gastrointestinal , hepatic , urinary tract , hepatobiliary disorder , mental disturbance Surgery gastrointestinal tract could interfere kinetics study drug ( except appendectomy ) History relevant orthostatic hypotension , faint spell , blackout Relevant chronic aAcute infections/ acute disease occur within 4 week inclusion study History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) Regular use medicinal product less 2 week investigational drug administration Intake systemic inhibitor inductor microsomal hepatic enzyme less 30 day investigational drug administration Intake drug long halflife ( Â¿24 hour ) within 30 day less 10 halflives respective drug prior administration trial medication Use drug might reasonably influence result trial base current knowledge within 14 day prior drug administration trial Participation another trial investigational drug administration within 3 month prior administration trial medication Alcohol intake = 10 unit alcohol per week ( 1 unit alcohol equal one 50 ml single measure distil alcoholic beverages/spirits ( ABV 40 % ) , 0.5 litre beer ( ABV 5 % ) , 200 ml glass red wine ( ABV 12 % ) history alcohol abuse , narcomania , drug abuse . Drug abuse Blood donation ( 100 mL within 30 day prior administration trial medication intend trial ) Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen per protocol per protocol procedure Subject assess investigator unsuitable inclusion , instance , consider able understand comply study requirement , condition would allow safe participation study Intake xanthinecontaining drink food alcohol 72 h screen second treatment period Intake drink food contain grapefruit , Chinese grapefruit , Seville oranges female subject : Positive pregnancy test , pregnancy plan become pregnant within 30 day study completion Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>